This clinical trial demonstrates the possibility of using recombinant BDNF and other neurotrophins to improve severe neurological conditions as other trials involving subcutaneous and intrathecal administration of BDNF are in progress for other conditions such as ALS and spinal cord injury [29]. This evidence concerns the gene BDNF and amyotrophic lateral sclerosis.